Tarsus Pharmaceuticals, Inc.
TARS
Rank in Stocks
#4648
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Share Price
$69.50
Market Cap
$3.25B
Change (1 day)
0.00%
Change (1 year)
-2.37%
Country
US
Trade Tarsus Pharmaceuticals, Inc. (TARS)
Category
Healthcare
Stock split history for Tarsus Pharmaceuticals, Inc. (TARS)
Tarsus Pharmaceuticals, Inc. stock (symbol: TARS) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One TARS share bought prior to Oct 20, 2026 would equal to 0 TARS shares today.
The most recent stock split occurred on Oct 20, 2026.
One TARS share bought prior to Oct 20, 2026 would equal to 0 TARS shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
